Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Bleeding

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    2,103 result(s) found for: Bleeding. Displaying page 78 of 106.
    «« First « Previous 74  75  76  77  78  79  80  81  82  Next» Last»»
    EudraCT Number: 2019-000583-18 Sponsor Protocol Number: SRA-MMB-301 Start Date*: 2020-01-07
    Sponsor Name:Sierra Oncology, Inc.
    Full Title: A Randomized, Double-Blind, Phase 3 Study to Evaluate the Activity of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic, Anemic Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera...
    Medical condition: Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis, or Post Essential Thrombocythemia Myelofibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028537 Myelofibrosis PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028538 Myelofibrosis with myelometaplasia LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074689 Post polycythemia vera myelofibrosis LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074690 Post essential thrombocythemia myelofibrosis LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074691 Post polycythaemia vera myelofibrosis LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074692 Post essential thrombocythaemia myelofibrosis LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077161 Primary myelofibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) SE (Completed) DK (Completed) FR (Completed) CZ (Completed) ES (Restarted) PL (Completed) HU (Completed) AT (Completed) IT (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2019-004294-13 Sponsor Protocol Number: RD.06.SPR.202699 Start Date*: 2020-10-05
    Sponsor Name:Galderma S.A.
    Full Title: A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects with Prurigo Nodularis
    Medical condition: Prurigo Nodularis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10037084 Prurigo nodularis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) SE (Trial now transitioned) GB (GB - no longer in EU/EEA) AT (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned) DK (Trial now transitioned) BE (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-003987-29 Sponsor Protocol Number: APD334-303 Start Date*: 2019-06-25
    Sponsor Name:Arena Pharmaceuticals Inc. a wholly owned subsidiary of Pfizer Inc.
    Full Title: An Open-Label Extension Study of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis
    Medical condition: Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10045365 Ulcerative colitis LLT
    20.1 10017947 - Gastrointestinal disorders 10045366 Ulcerative colitis, unspecified LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Trial now transitioned) BE (Trial now transitioned) NL (Ongoing) CZ (Trial now transitioned) EE (Ongoing) FR (Trial now transitioned) LV (Completed) HU (Trial now transitioned) DE (Trial now transitioned) DK (Completed) AT (Completed) BG (Trial now transitioned) PL (Trial now transitioned) PT (Trial now transitioned) LT (Trial now transitioned) ES (Ongoing) HR (Completed) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-002136-24 Sponsor Protocol Number: 0157 Start Date*: 2019-09-10
    Sponsor Name:Theravance Biopharma Ireland Limited
    Full Title: A Phase 2b/3 Multi-Center, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled, Parallel-Group Set of Studies to Evaluate the Efficacy and Safety of Induction and Maintenance Therapy with TD-1...
    Medical condition: Moderately-to-Severely Active Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10066678 Acute ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) DE (Completed) SK (Prematurely Ended) PT (Prematurely Ended) BG (Prematurely Ended) PL (Completed) GR (Prematurely Ended) HU (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) RO (Completed)
    Trial results: View results
    EudraCT Number: 2013-003301-26 Sponsor Protocol Number: IAFIPF001 Start Date*: 2013-09-20
    Sponsor Name:Newcastle Upon Tyne Hospitals NHS Foundation Trust
    Full Title: A randomised placebo-controlled pilot trial of omeprazole in idiopathic pulmonary fibrosis (IPF)
    Medical condition: Idiopathic Pulmonary Fibrosis (IPF)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-002076-41 Sponsor Protocol Number: 0667 Start Date*: 2018-08-23
    Sponsor Name:University of Leicester
    Full Title: A RANDOMISED CONTROLLED TRIAL OF PRE-SURGERY SODIUM VALPROATE, FOR THE PREVENTION OF ORGAN INJURY IN CARDIAC SURGERY: Val-CARD
    Medical condition: Reduction of myocardial and kidney injury risk of post cardiac surgery by increasing the expression of genes that promote myocardial mitochondrial homeostasis via effects on chromatin histone deace...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10069339 Acute kidney injury PT
    20.1 100000004849 10057768 Post-cardiac injury syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-002085-13 Sponsor Protocol Number: KX-ORAX-010 Start Date*: 2019-12-30
    Sponsor Name:Athenex, Inc
    Full Title: A Pilot Study of Oraxol in Subjects with Cutaneous Angiosarcoma
    Medical condition: Study of Oraxol in Subjects with Cutaneous Angiosarcoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002477 Angiosarcoma metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2008-004175-22 Sponsor Protocol Number: HC-G-H-0803 Start Date*: Information not available in EudraCT
    Sponsor Name:B. Braun Melsungen AG
    Full Title: PROSPECTIVE, CONTROLLED, DOUBLE-BLIND, RANDOMIZED MULTICENTRIC STUDY ON THE EFFICACY AND SAFETY OF A TARGET CONTROLLED PLASMA VOLUME REPLACEMENT THERAPY WITH A HYPER-ONCOTIC BALANCED HES 130/0.42...
    Medical condition: Intraoperative plasma volume replacement requirement in elective surgery of the pancreatic head (pylorus preserving pancreatic-duodenectomy, PPPD)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10022891 - Investigations 10059909 Volume plasma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-003391-37 Sponsor Protocol Number: Scil-MD05-C01 Start Date*: 2005-12-05
    Sponsor Name:Scil Technology GmbH
    Full Title: Pilot Study on Safety and explorative Efficacy of MD05 in Comparison with the Medical Device Beta-TCP Mixed with Autogenous Bone Material in Patients Undergoing Two-Stage Unilateral Maxillary Sinus...
    Medical condition: Requirement of two-stage unilateral maxillary sinus floor augmentation in case of insufficient bone height in the area of the posterior maxilla, prior to insertion of dental implants.
    Disease: Version SOC Term Classification Code Term Level
    8.0 10061257 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020678-41 Sponsor Protocol Number: FARM7SJ7X9 Start Date*: 2009-07-07
    Sponsor Name:AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE
    Full Title: USE OF SORAFENIB IN THE PREVENTION OF RELAPSE OF RESECTED/ABLATED HEPATOCELLULAR CARCINOMA (HCC) IN PATIENTS WITH HEPATITIS C VIRUS CHRONIC INFECTION.
    Medical condition: Patients HCV RNA positive with HCC, surgical resection or percutaneous tumor ablation procedures
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029104 SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-001283-37 Sponsor Protocol Number: GE-ARNICA-2008 Start Date*: 2007-09-24
    Sponsor Name:AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA
    Full Title: Chronic hepatitis C in illicit drug users and the role of antiviral therapy: the ARNICA project (Antiviral tReatment for chroNic hepatItis C in Active substance users)
    Medical condition: Chronic Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019715 Hepatic viral infections HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-006311-21 Sponsor Protocol Number: CBAF312A2202 Start Date*: 2009-07-28
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-centre, double-blind, placebo controlled, proof of concept study to evaluate the efficacy and tolerability of BAF312 in patients with polymyositis and dermatomyositis
    Medical condition: Polymyositis and dermatomyositis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036102 Polymyositis LLT
    9.1 10012503 Dermatomyositis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) SE (Prematurely Ended) HU (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2011-003695-36 Sponsor Protocol Number: Start Date*: 2012-09-07
    Sponsor Name:Brighton & Sussex University Hospitals NHS Trust
    Full Title: Is intravenous iron and darbepoetin more effective than oral iron in reducing blood transfusion requirements for patients undergoing cardiac surgery
    Medical condition: Anaemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10066761 Acute anaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-006451-52 Sponsor Protocol Number: 4474 Start Date*: 2009-01-27
    Sponsor Name:Newcastle upon Tyne Hospitals NHS Foundation Trust
    Full Title: An investigation of the association between vitamin K intake, vitamin K epoxide reductase subunit (VKORC1) genotype and anticoagulation response to warfarin
    Medical condition: Patients will be recruited who are receiving long term warfarin therapy for the treatment or prevention of venous or arterial thrombosis or embolism
    Disease: Version SOC Term Classification Code Term Level
    9.1 10043566 Thromboembolism LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-019461-29 Sponsor Protocol Number: ETAMI Start Date*: 2011-03-25
    Sponsor Name:Stiftung Institut für Herzinfarktforschung
    Full Title: ETAMI-Study: Early Thienopyridine treatment to improve primary PCI in Patients with Acute Myocardial Infarction
    Medical condition: Myocardial infarction <= 12 hours
    Disease: Version SOC Term Classification Code Term Level
    15.0 10007541 - Cardiac disorders 10000891 Acute myocardial infarction PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004200-38 Sponsor Protocol Number: N11RFA Start Date*: 2012-03-28
    Sponsor Name:NKI-AVL
    Full Title: Phase II study exploring safety and efficacy of the combination of ipilimumab with radiofrequency ablation (RFA) in patients with unresectable uveal melanoma liver metastasis (SECIRA-UM)
    Medical condition: Unresectable uveal melanoma liver metastasis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10015919 - Eye disorders 10030052 Ocular melanomas HLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-001284-40 Sponsor Protocol Number: 160315 Start Date*: 2015-05-20
    Sponsor Name:Aarhus University Hospital
    Full Title: The effect of liraglutide on bone turnover, bone mass and bone cell function
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004861 10029505 Non-insulin-dependent diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2014-004882-26 Sponsor Protocol Number: ND-L02-s0201-002 Start Date*: 2015-03-25
    Sponsor Name:Nitto Denko Corporation
    Full Title: A Phase 1b/2, Open Label, Randomized, Repeat Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Biological Activity and Pharmacokinetics of ND L02 s0201 Injection, a Vitamin A-couple...
    Medical condition: Moderate to extensive progressive hepatic fibrosis (METAVIR F3-4)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10019805 - Hepatobiliary disorders 10019668 Hepatic fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2015-001401-13 Sponsor Protocol Number: RRK5174 Start Date*: 2016-04-07
    Sponsor Name:University Hospitals Birmingham NHS Foundation Trust
    Full Title: A Multi-Centre Randomised Controlled Trial of Pre-Hospital Blood Product Administration versus Standard Care for Traumatic Haemorrhage
    Medical condition: Hypotension after trauma, due to haemorrhage
    Disease: Version SOC Term Classification Code Term Level
    18.1 10022117 - Injury, poisoning and procedural complications 10053476 Traumatic haemorrhage PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-004335-36 Sponsor Protocol Number: ANAVEX2-73-PDD-001 Start Date*: 2018-07-04
    Sponsor Name:Anavex Life Sciences Corp.
    Full Title: A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73 for Cognitive Impairment in Parkinson’s Disease with Dementia Patients.
    Medical condition: Cognition in Parkinson’s Disease with dementia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 74  75  76  77  78  79  80  81  82  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 15 08:30:21 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA